Cost-Effectiveness Analysis of Olaparib in Combination with Bevacizumab Compared with Bevacizumab Monotherapy for the First-Line Maintenance Treatment of Homologous Recombination Deficiency-Positive Advanced Ovarian Cancer

被引：0
|
作者：
David Elsea
Lin Fan
Adela Mihai
Fadoua El Moustaid
Daniel Simmons
Matthew Monberg
Dominic Muston
机构：
[1] Formerly of Lumanity,
[2] Inc.,undefined
[3] Formerly of Merck & Co.,undefined
[4] Inc.,undefined
[5] AstraZeneca,undefined
[6] AstraZeneca,undefined
[7] Merck & Co.,undefined
[8] Inc.,undefined
来源：
PharmacoEconomics - Open | 2022年 / 6卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：811 / 822
页数：11
相关论文
共 50 条
  • [21] Cost-effectiveness analysis of the addition of bevacizumab to first-line chemotherapy in metastatic colorectal cancer
    Villa, D.
    Hedden, L.
    Peacock, S.
    Kennecke, H. F.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [22] First-line treatment of women with advanced ovarian cancer: focus on bevacizumab
    Marchetti, Claudia
    Muzii, Ludovico
    Romito, Alessia
    Panici, Pierluigi Benedetti
    ONCOTARGETS AND THERAPY, 2019, 12 : 1095 - 1103
  • [23] NICE guidance on bevacizumab in combination with paclitaxel and carboplatin for the first-line treatment of advanced ovarian cancer
    Dyer, Matthew
    Richardson, Joanna
    Robertson, Janet
    Adam, Jane
    LANCET ONCOLOGY, 2013, 14 (08): : 689 - 690
  • [24] Bevacizumab with Chemotherapy as a First-Line Treatment for Advanced Ovarian Cancer in a Serbian Cohort
    Conic, Irena
    Nedovic, Bojan
    Stojnev, Slavica
    Todorovska, Ilinka
    Dimitrijevic, Aleksandra
    Krstic, Miljan
    Djordjevic, Ivana
    Djordjevic, Biljana
    MEDICINA-LITHUANIA, 2022, 58 (05):
  • [25] Atezolizumab plus bevacizumab versus nivolumab as first-line treatment for advanced or unresectable hepatocellular carcinoma: A cost-effectiveness analysis
    Li, Yan
    Liang, Xueyan
    Li, Huijuan
    Chen, Xiaoyu
    CANCER, 2022, 128 (22) : 3995 - 4003
  • [26] Cost-effectiveness analysis of sintilimab plus bevacizumab biosimilar compared with lenvatinib as the first-line treatment of unresectable or metastatic hepatocellular carcinoma
    Ting Zhou
    Xintian Wang
    Yingdan Cao
    Lan Yang
    Zijing Wang
    Aixia Ma
    Hongchao Li
    BMC Health Services Research, 22
  • [27] Cost-Effectiveness Analysis of Panitumumab Compared with Bevacizumab for First-Line Treatment of Patients with Wild-Type RAS Metastatic Colorectal Cancer in Germany
    Frank, M.
    Lange, A.
    Michailov, G.
    Lebioda, A.
    GESUNDHEITSOEKONOMIE UND QUALITAETSMANAGEMENT, 2016, 21 (04): : 203 - 209
  • [28] Cost-effectiveness analysis of sintilimab plus bevacizumab biosimilar compared with lenvatinib as the first-line treatment of unresectable or metastatic hepatocellular carcinoma
    Zhou, Ting
    Wang, Xintian
    Cao, Yingdan
    Yang, Lan
    Wang, Zijing
    Ma, Aixia
    Li, Hongchao
    BMC HEALTH SERVICES RESEARCH, 2022, 22 (01)
  • [29] Atezolizumab and bevacizumab combination compared with sorafenib as the first-line systemic treatment for patients with unresectable hepatocellular carcinoma: A cost-effectiveness analysis in China and the United states
    Wen, Feng
    Zheng, Hanrui
    Zhang, Pengfei
    Liao, Weiting
    Zhou, Kexun
    Li, Qiu
    LIVER INTERNATIONAL, 2021, 41 (05) : 1097 - 1104
  • [30] OLAPARIB AS MAINTENANCE THERAPY FOR WOMEN WITH OVARIAN CANCER AND HOMOLOGOUS RECOMBINATION DEFICIENCY IN BRAZIL: WHAT CLINICAL AND COST DATA HAVE HIGHEST IMPACT ON COST-EFFECTIVENESS ANALYSIS?
    Okumura, L.
    Massaoka, M. H.
    Areas, I
    Licursi, C.
    Mihai, A.
    Ryan, J.
    VALUE IN HEALTH, 2022, 25 (07) : S345 - S345
12345